Janux Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

JANX$12.04-5.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Statements of Stockholders’ Equity

For the Six Months Ended June 30, 2024 and 2023

(in thousands, except share data)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2023	46,252,440	$46	$512,401	$665	$(168,763)	$344,349
Issuance of common stock and pre-funded common stock warrants, net of $20,913 of issuance costs	5,397,301	5	320,054	—	—	320,059
Exercise of common stock options	441,368	1	4,403	—	—	4,404
Shares issued under employee stock purchase plan	63,070	—	473	—	—	473
Vesting of restricted shares	8,036	—	10	—	—	10
Stock-based compensation	—	—	11,382	—	—	11,382
Unrealized loss on available-for-sale securities, net	—	—	—	(2,281)	—	(2,281)
Net loss	—	—	—	—	(20,719)	(20,719)
Balance at June 30, 2024	52,162,215	$52	$848,723	$(1,616)	$(189,482)	$657,677

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Loss	Deficit	Equity
Balance at December 31, 2022	41,616,260	$42	$432,703	$(1,535)	$(110,470)	$320,740
Exercise of common stock options	148,649	—	1,580	—	—	1,580
Shares issued under employee stock purchase plan	57,911	—	528	—	—	528
Vesting of restricted shares	44,716	—	139	—	—	139
Stock-based compensation	—	—	10,974	—	—	10,974
Unrealized gain on available-for-sale securities, net	—	—	—	475	—	475
Net loss	—	—	—	—	(34,967)	(34,967)
Balance at June 30, 2023	41,867,536	$42	$445,924	$(1,060)	$(145,437)	$299,469

Unaudited Condensed Statements of Stockholders’ Equity

For the Three Months Ended June 30, 2024 and 2023

(in thousands, except share data)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Loss	Deficit	Equity
Balance at March 31, 2024	51,840,571	$51	$839,759	$(524)	$(183,523)	$655,763
Issuance costs	—	—	(17)	—	—	(17)
Exercise of common stock options	255,086	1	2,746	—	—	2,747
Shares issued under employee stock purchase plan	63,070	—	473	—	—	473
Vesting of restricted shares	3,488	—	5	—	—	5
Stock-based compensation	—	—	5,757	—	—	5,757
Unrealized loss on available-for-sale securities, net	—	—	—	(1,092)	—	(1,092)
Net loss	—	—	—	—	(5,959)	(5,959)
Balance at June 30, 2024	52,162,215	$52	$848,723	$(1,616)	$(189,482)	$657,677

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Loss	Deficit	Equity
Balance at March 31, 2023	41,802,807	$42	$439,890	$(739)	$(127,929)	$311,264
Shares issued under employee stock purchase plan	57,911	—	528	—	—	528
Vesting of restricted shares	6,818	—	5	—	—	5
Stock-based compensation	—	—	5,501	—	—	5,501
Unrealized loss on available-for-sale securities, net	—	—	—	(321)	—	(321)
Net loss	—	—	—	—	(17,508)	(17,508)
Balance at June 30, 2023	41,867,536	$42	$445,924	$(1,060)	$(145,437)	$299,469

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.